DOCSLIB.ORG

Generic Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ALENDRONATE SODIUM CLONIDINE HCL ALFUZOSIN HCL CLOPIDOGREL BISULFATE ALLOPURINOL CYANOCOBALAMIN (VITAMIN B-12) ALPRAZOLAM CYCLOBENZAPRINE HCL AMILORIDE HCL CYCLOPENTOLATE HCL AMILORIDE/HYDROCHLOROTHIAZIDE DESOG-E.ESTRADIOL/E.ESTRADIOL AMIODARONE HCL DESOGESTREL-ETHINYL ESTRADIOL AMITRIPTYLINE HCL DIAZEPAM AMLODIPINE BESYLATE DICYCLOMINE HCL AMLODIPINE BESYLATE/BENAZEPRIL DIGOXIN AMOXICILLIN DIPHENHYDRAMINE HCL AMPICILLIN TRIHYDRATE DONEPEZIL HCL ANASTROZOLE DORZOLAMIDE HCL ASCORBIC ACID DORZOLAMIDE HCL/TIMOLOL MALEAT ATENOLOL DOXAZOSIN MESYLATE ATENOLOL/CHLORTHALIDONE DULOXETINE HCL ATORVASTATIN CALCIUM DUTASTERIDE AZELASTINE HCL ENALAPRIL MALEATE BACLOFEN ENALAPRIL/HYDROCHLOROTHIAZIDE BENAZEPRIL HCL ERGOCALCIFEROL (VITAMIN D2) BENZTROPINE MESYLATE ESCITALOPRAM OXALATE BETHANECHOL CHLORIDE ESOMEPRAZOLE MAGNESIUM BISOPROLOL FUMARATE ESZOPICLONE BISOPROLOL/HYDROCHLOROTHIAZIDE ETHYNODIOL D-ETHINYL ESTRADIOL BUPROPION HCL EZETIMIBE BUSPIRONE HCL FAMOTIDINE CALCITRIOL FENOFIBRATE CARBIDOPA/LEVODOPA FENOFIBRATE NANOCRYSTALLIZED CARISOPRODOL FEXOFENADINE HCL CARVEDILOL FINASTERIDE CELECOXIB FLUDROCORTISONE ACETATE CETIRIZINE HCL FLUORIDE (SODIUM) CHLORDIAZEPOXIDE HCL FLUOXETINE HCL CHLORHEXIDINE GLUCONATE FLURBIPROFEN CHLORTHALIDONE FLURBIPROFEN SODIUM CILOSTAZOL FLUTICASONE PROPIONATE CIPROFLOXACIN HCL FOLIC ACID CITALOPRAM HYDROBROMIDE FORMALDEHYDE CLONAZEPAM FOSINOPRIL SODIUM Effective January 1, 2020 FUROSEMIDE LITHIUM CARBONATE GABAPENTIN LORAZEPAM GEMFIBROZIL LOSARTAN POTASSIUM GENTAMICIN SULFATE LOSARTAN/HYDROCHLOROTHIAZIDE GLIMEPIRIDE LOVASTATIN GLIPIZIDE MAPROTILINE HCL GLYBURIDE MECLIZINE HCL GLYBURIDE,MICRONIZED MEDROXYPROGESTERONE ACETATE GLYBURIDE/METFORMIN HCL MEFLOQUINE HCL GUANFACINE HCL MEGESTROL ACETATE HALOPERIDOL MELOXICAM HALOPERIDOL LACTATE METFORMIN HCL HOMATROPINE HBR METHADONE HCL HYDRALAZINE HCL METHIMAZOLE HYDROCHLOROTHIAZIDE METHOCARBAMOL HYDROXYUREA METHOTREXATE SODIUM/PF HYDROXYZINE HCL METHYLDOPA HYDROXYZINE PAMOATE METOCLOPRAMIDE HCL IBANDRONATE SODIUM METOPROLOL SUCCINATE IBUPROFEN METOPROLOL TARTRATE IMIPRAMINE HCL MICONAZOLE NITRATE INDAPAMIDE MIDAZOLAM HCL INDOMETHACIN MINOXIDIL IPRATROPIUM/ALBUTEROL SULFATE MIRTAZAPINE IRBESARTAN MONTELUKAST SODIUM ISONIAZID MULTIVITAMIN/IRON/FOLIC ACID ISOSORBIDE MONONITRATE MUPIROCIN LABETALOL HCL NABUMETONE LANOLIN ALCOHOL/MO/W.PET/CERES NAPROXEN LATANOPROST NIACINAMIDE LETROZOLE NIFEDIPINE LEVETIRACETAM NIZATIDINE LEVOCETIRIZINE DIHYDROCHLORIDE NORETHINDRONE LEVOFLOXACIN NORETHINDRONE AC-ETH ESTRADIOL LEVONORGESTREL-ETHIN ESTRADIOL NORETHINDRONE-E.ESTRADIOL-IRON LEVOTHYROXINE SODIUM NORETHINDRONE-ETHINYL ESTRAD LIOTHYRONINE SODIUM NORGESTIMATE-ETHINYL ESTRADIOL LISINOPRIL NORGESTREL-ETHINYL ESTRADIOL LISINOPRIL/HYDROCHLOROTHIAZIDE NORTRIPTYLINE HCL Effective January 1, 2020 OLANZAPINE QUINAPRIL HCL OLMESARTAN MEDOXOMIL RABEPRAZOLE SODIUM OMEPRAZOLE RAMIPRIL ONDANSETRON HCL RANITIDINE HCL ONDANSETRON HCL/PF RISPERIDONE ORPHENADRINE CITRATE ROPINIROLE HCL OXYBUTYNIN CHLORIDE ROSUVASTATIN CALCIUM PANTOPRAZOLE SODIUM SERTRALINE HCL PAROXETINE HCL SILVER SULFADIAZINE PENICILLIN V POTASSIUM SIMVASTATIN PENTOXIFYLLINE SODIUM BICARBONATE PERINDOPRIL ERBUMINE SODIUM CHLORIDE PHENTERMINE HCL SODIUM CHLORIDE FOR INHALATION PHENYLEPHRINE HCL SODIUM CHLORIDE IRRIG SOLUTION PHENYTOIN SOTALOL HCL PHENYTOIN SODIUM EXTENDED SPIRONOLACTONE PIOGLITAZONE HCL SULFAMETHOXAZOLE/TRIMETHOPRIM PNV 15/IRON FUM,PS/FOLIC ACID SULINDAC PNV,CALCIUM 72/IRON,CARB/FOLIC SYRINGE-NEEDLE,INSULIN,0.5 ML PNV,CALCIUM 72/IRON/FOLIC ACID TAMOXIFEN CITRATE POLYMYXIN B SULF/TRIMETHOPRIM TAMSULOSIN HCL POTASSIUM BICARBONATE/CIT AC TEMAZEPAM POTASSIUM CHLORIDE TERAZOSIN HCL PRAMIPEXOLE DI-HCL TERBINAFINE HCL PRAVASTATIN SODIUM TETRACAINE HCL PREDNISONE THIAMINE HCL PRENATAL VIT 14/IRON FUM/FOLIC THIOTHIXENE PRENATAL VIT,CAL 74/IRON/FOLIC THYROID,PORK PRENATAL VIT,CALC76/IRON/FOLIC TIZANIDINE HCL PRENATAL VIT,CALC78/IRON/FOLIC TOPIRAMATE PRENATAL VIT27,CALCIUM/IRON/FA TORSEMIDE PRIMIDONE TRAMADOL HCL PROCHLORPERAZINE MALEATE TRANDOLAPRIL PROGESTERONE, MICRONIZED TRAZODONE HCL PROMETHAZINE HCL/CODEINE TRIAMCINOLONE ACETONIDE PROMETHAZINE/DEXTROMETHORPHAN TRIAMTERENE/HYDROCHLOROTHIAZID PROPRANOLOL HCL TRIHEXYPHENIDYL HCL PROPRANOLOL/HYDROCHLOROTHIAZID TRIMETHOPRIM QUETIAPINE FUMARATE TROPICAMIDE Effective January 1, 2020 VALACYCLOVIR HCL VALSARTAN VENLAFAXINE HCL WARFARIN SODIUM WATER FOR INJECTION,STERILE ZALEPLON ZOLPIDEM TARTRATE ZONISAMIDE Effective January 1, 2020.
Recommended publications
  • Long-Term Statin Use and Risk of Ductal and Lobular Breast Cancer Among Women 55 to 74 Years of Age

    Long-Term Statin Use and Risk of Ductal and Lobular Breast Cancer Among Women 55 to 74 Years of Age

    Published OnlineFirst July 5, 2013; DOI: 10.1158/1055-9965.EPI-13-0414 Cancer Epidemiology, Research Article Biomarkers & Prevention Long-Term Statin Use and Risk of Ductal and Lobular Breast Cancer among Women 55 to 74 Years of Age Jean A. McDougall1, Kathleen E. Malone1, Janet R. Daling1, Kara L. Cushing-Haugen1, Peggy L. Porter1,2, and Christopher I. Li1 Abstract Background: Mechanistic studies largely support the chemopreventive potential of statins. However, results of epidemiologic studies investigating statin use and breast cancer risk have been inconsistent and lacked the ability to evaluate long-term statin use. Methods: We used data from a population-based case–control study of breast cancer conducted in the Seattle–Puget Sound region to investigate the relationship between long-term statin use and breast cancer risk. Nine hundred sixteen invasive ductal carcinoma (IDC) and 1,068 invasive lobular carcinoma (ILC) cases in patients 55 to 74 years of age diagnosed between 2000 and 2008 were compared with 902 control women. All participants were interviewed in-person and data on hypercholesterolemia and all episodes of lipid-lowering medication use were collected through a structured questionnaire. We assessed the relationship between statin use and IDC and ILC risk using polytomous logistic regression. Results: Current users of statins for 10 years or longer had a 1.83-fold increased risk of IDC [95% confidence interval (CI): 1.14–2.93] and a 1.97-fold increased risk of ILC (95% CI: 1.25–3.12) compared with never users of statins. Among women diagnosed with hypercholesterolemia, current users of statins for 10 years or longer had more than double the risk of both IDC (OR: 2.04, 95% CI: 1.17–3.57) and ILC (OR: 2.43, 95% CI: 1.40–4.21) compared with never users.
  • Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)

    Appendix A: Potentially Inappropriate Prescriptions (Pips) for Older People (Modified from ‘STOPP/START 2’ O’Mahony Et Al 2014)

    Appendix A: Potentially Inappropriate Prescriptions (PIPs) for older people (modified from ‘STOPP/START 2’ O’Mahony et al 2014) Consider holding (or deprescribing - consult with patient): 1. Any drug prescribed without an evidence-based clinical indication 2. Any drug prescribed beyond the recommended duration, where well-defined 3. Any duplicate drug class (optimise monotherapy) Avoid hazardous combinations e.g.: 1. The Triple Whammy: NSAID + ACE/ARB + diuretic in all ≥ 65 year olds (NHS Scotland 2015) 2. Sick Day Rules drugs: Metformin or ACEi/ARB or a diuretic or NSAID in ≥ 65 year olds presenting with dehydration and/or acute kidney injury (AKI) (NHS Scotland 2015) 3. Anticholinergic Burden (ACB): Any additional medicine with anticholinergic properties when already on an Anticholinergic/antimuscarinic (listed overleaf) in > 65 year olds (risk of falls, increased anticholinergic toxicity: confusion, agitation, acute glaucoma, urinary retention, constipation). The following are known to contribute to the ACB: Amantadine Antidepressants, tricyclic: Amitriptyline, Clomipramine, Dosulepin, Doxepin, Imipramine, Nortriptyline, Trimipramine and SSRIs: Fluoxetine, Paroxetine Antihistamines, first generation (sedating): Clemastine, Chlorphenamine, Cyproheptadine, Diphenhydramine/-hydrinate, Hydroxyzine, Promethazine; also Cetirizine, Loratidine Antipsychotics: especially Clozapine, Fluphenazine, Haloperidol, Olanzepine, and phenothiazines e.g. Prochlorperazine, Trifluoperazine Baclofen Carbamazepine Disopyramide Loperamide Oxcarbazepine Pethidine
  • What Precautions Should We Use with Statins for Women of Childbearing

    What Precautions Should We Use with Statins for Women of Childbearing

    CLINICAL INQUIRIES What precautions should we use with statins for women of childbearing age? Chaitany Patel, MD, Lisa Edgerton, PharmD New Hanover Regional Medical Center, Wilmington, North Carolina Donna Flake, MSLS, MSAS Coastal Area Health Education Center, Wilmington, NC EVIDENCE- BASED ANSWER Statins are contraindicated for women who are on its low tissue-penetration properties. pregnant or breastfeeding. Data evaluating statin Cholesterol-lowering with simvastatin 40 mg/d did use for women of childbearing age is limited; how- not disrupt menstrual cycles or effect luteal phase ever, they may be used cautiously with adequate duration (strength of recommendation: C). contraception. Pravastatin may be preferred based CLINICAL COMMENTARY Use statins only as a last resort Before reading this review, I had not been for women of childbearing age ® Dowdenaware Health of the serious Media effects of statin medications I try to follow the USPSTF recommendations and on the developing fetus. In conversations with not screen women aged <45 years without coro- my colleagues, I found that the adverse effects nary artery disease riskCopyright factors for Fhyperlipidemia.or personalof usestatins onlyduring pregnancy are not readily When a woman of any age needs treatment, my known. Such information needs to be more first-line therapy is lifestyle modification. Given the widely disseminated. risks of statin drugs to the developing fetus, Ariel Smits, MD women with childbearing potential should give Department of Family Medicine, Oregon Health & Science fully informed consent and be offered reliable University, Portland contraception before stating statin therapy. I Evidence summary anal, cardiac, tracheal, esophageal, renal, Hydroxymethyl glutaryl coenzyme A and limb deficiency (VACTERL associa- (HMG CoA) reductase inhibitors, com- tion), intrauterine growth retardation monly called statins, have been on the (IUGR), and demise in fetuses exposed market since the late 1980s.
  • Medication Dental Watch List Risk for Reflux Risk for Caries

    Medication Dental Watch List Risk for Reflux Risk for Caries

    Risk for Stomatitis Risk for Xerostomia Generic and Trade Name Medication Dental Watch List Risk for Reflux Risk for Caries Abilify Celexa Exenatide Itraconazole Naproxen Sinequan Acamprosate Cetirizine Famotidine Ketorolac Neurontin Sporanox Accutane Chantix Feldene Kytril Nexium Strattera Actiq Chlorpromazine Felodipine Lamivudine Nifedipine Subutex Adalat Cholestryramine Fentanyl Lansoprazole Nitro-Bid Sulfamethoxazole Advair Cialis Fentanyl (transmucosal) Levalbuterol Nitro-Dur Sulfasalazine Aldomet Citalopram Flexeril Levbid Nitroglycerin Sulfatrim Alendronate Clarithromycin Flonase Levocarnitine Nitrostat Sumatriptan Alfuzosin Claritin Flovent Levocetirizine Nortriptyline Tacrine Aliskiren Clomipramine Fluoxetine Levodopa Oxybutynin Tadalafil Alprazolam Clonidine Fluticasone Lexapro Pamelor Tegretol Amitriptyline Clozapine Fluvoxamine Lioresal Pentasa Tekturna Anafranil Clozaril Fosamax Lisdexamfetamine Pepcid Tenex Antivert Cognex Fosinopril Lisinopril Periactin Thorazine Aripiprazole Combivir Gabapentin Lithium Piroxicam Tofranil Asacol Copegus Gemfibrozil Locholest Plaquenil Toprol Aspirin Cozaar Granisetron Loperamide Plendil Toradol Atarax Cyclobenzaprine Guanfacine Lopid Prevacid Trexall Atomoxetine Cymbalta Haldol Lopressor Prevalite UroXatral Atrovent Cyproheptadine Haloperidol Loratadine Prinivil Varenicline Azulfidine Cytotec Hydroxychloroquine Losartan ProAmatine Vasotec Baclofen Darifenacin Hydroxyzine Luvox Procardia Versed Biaxin Diflunisal Hyoscyamine Meclizine Propranolol Vistaril Budesonide Ditropan Ibuprofen Mesalamine
  • Department of Health

    Department of Health

    DEPARTMENT OF HEALTH National Drug Policy - Pharmaceutical Management Unit 50 National Formulary Committee Philippine National Drug Formulary EssentialEssential MedicinesMedicines ListList Volume I, 7th Edition ( 2008 ) Published by: The National Formulary Committee National Drug Policy ‐ Pharmaceutical Management Unit 50 DEPARTMENT OF HEALTH Manila, Philippines All rights reserved 2008 The National Formulary Committee National Drug Policy‐Pharmaceutical Management Unit 50 (NDP‐PMU 50) Department of Health San Lazaro Cmpd., Rizal Ave., Sta. Cruz, Manila, Philippines 1003 ISBN 978‐971‐91620‐7‐0 Any part or the whole book may be reproduced or transmitted without any alteration, in any form or by any means, with permission from DOH provided it is not sold commercially. ii PHILIPPINE NATIONAL DRUG FORMULARY Volume I, 7th Edition 2 0 0 8 Francisco T. Duque III, MD, MSc Secretary of Health Alexander A. Padilla Undersecretary of Health, Office for External Affairs Robert Louie P. So, MD Program Manager, NDP-PMU 50 Dennis S. Quiambao, MD Proj. Mgmt. Operating Officer & Coordinator (PMOOC) NDP-PMU 50 NATIONAL FORMULARY COMMITTEE Estrella B. Paje-Villar, MD, DTM & H Chairperson Jose M. Acuin, MD, MSc Alma L. Jimenez, MD Alejandro C. Baroque II, MD Marieta B. de Luna, MD Bu C. Castro, MD Nelia P. Cortes-Maramba, MD Dina V. Diaz, MD Yolanda R. Robles, PhD Pharm Mario R. Festin, MD, MS, MHPEd Isidro C. Sia, MD BFAD Representative SECRETARIAT Luzviminda O. Marquez, RPh, RMT Mary Love C. Victoria, RPh Michael D. Junsay, RPh Ermalyn M. Magturo iii Republic of the Philippines DEPARTMENT OF HEALTH OFFICE OF THE SECRETARY 2/F Bldg. 1, San Lazaro Cmpd., Rizal Avenue, Sta.
  • New Zealand Data Sheet 1. Product Name

    New Zealand Data Sheet 1. Product Name

    NEW ZEALAND DATA SHEET 1. PRODUCT NAME Norvir 100 mg tablets. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 100 mg ritonavir. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM White film-coated oval tablets debossed with the corporate Abbott "A" logo and the Abbott-Code “NK”. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications NORVIR is indicated for use in combination with appropriate antiretroviral agents or as monotherapy if combination therapy is inappropriate, for the treatment of HIV-1 infection in adults and children aged 12 years and older. For persons with advanced HIV disease, the indication for ritonavir is based on the results for one study that showed a reduction in both mortality and AIDS defining clinical events for patients who received ritonavir. Median duration of follow-up in this study was 6 months. The clinical benefit from ritonavir for longer periods of treatment is unknown. For persons with less advanced disease, the indication is based on changes in surrogate markers in controlled trials of up to 16 weeks duration (see section 5.1 Pharmacodynamic properties). 4.2 Dose and method of administration General Dosing Guidelines Prescribers should consult the full product information and clinical study information of protease inhibitors if they are co-administered with a reduced dose of ritonavir. The recommended dose of NORVIR is 600 mg (six tablets) twice daily by mouth, and should be given with food. NORVIR tablets should be swallowed whole and not chewed, broken or crushed. NORVIR DS 29 April 2020 Page 1 of 37 Version 35 Paediatric population Ritonavir has not been studied in patients below the age of 12 years; hence the safety and efficacy of ritonavir in children below the age of 12 have not been established.
  • Guideline for Preoperative Medication Management

    Guideline for Preoperative Medication Management

    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
  • First Dose Efficacy of Alfuzosin Once Daily in Men with Symptomatic Benign Prostatic Hyperplasia

    First Dose Efficacy of Alfuzosin Once Daily in Men with Symptomatic Benign Prostatic Hyperplasia

    ADULT UROLOGY FIRST DOSE EFFICACY OF ALFUZOSIN ONCE DAILY IN MEN WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA LEONARD S. MARKS, CLAUS G. ROEHRBORN, MARC GITTELMAN, DANIEL KIM, JOHN FORREST, AND SHARON JACOBS ABSTRACT Objectives. To evaluate the onset of action of alfuzosin once daily (OD) as determined by uroflowmetry early after initial dosing. Alfuzosin OD is an extended-release formulation of a uroselective, alpha1-adrenorecep- tor-blocking agent (alpha-blocker) used in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Methods. This was a randomized, placebo-controlled, two-way Latin square crossover study. Forty-nine patients were selected for this study on the basis of their symptomatic improvement during previous treatment with alpha-blockers and significant decreases in urinary flow rate when that treatment was withdrawn. Results. Our analysis showed that significant increases in the maximal urinary flow rate (Qmax) in 34 assessable patients occurred as soon as 8 hours after the initial dose of medication and persisted for at least 4 days. The ⌬Qmax for alfuzosin 10 mg OD was 3.2 mL/s and for placebo it was 1.1 mL/s. The difference of means for the assessable population was 2.1 (95% confidence interval 0.8 to 3.4, P ϭ 0.002). The overall incidence of adverse events was low. Only dizziness, experienced by 3 patients treated with alfuzosin compared with 1 patient treated with placebo, appeared to be related to the study drug. Conclusions. Together, our findings suggest that alfuzosin OD exhibits a urodynamically measurable effect on bladder outlet obstruction due to benign prostatic hyperplasia in men with lower urinary tract symptoms within hours of the first administration.
  • Comparison of Different Alpha-Blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms

    Comparison of Different Alpha-Blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms

    대한남성과학회지：제 29 권 제 3 호 2011년 12월 Korean J Androl. Vol. 29, No. 3, December 2011 http://dx.doi.org/10.5534/kja.2011.29.3.242 Comparison of Different Alpha-blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms Keon Cheol Lee1, Jong Gu Kim2, Sung Yong Cho1, Joon Sung Jeon1, In Rae Cho1 Department of Urology, 1Inje University Ilsanpaik Hospital, Goyang, 2Happy Urology Clinic, Ansan, Korea =Abstract= Purpose: We compared the efficacy and safety profiles of dose increase, traditional combination methods, and combining different alpha blockers in hypertensive males with lower urinary tract symptom (LUTS) refractory to an initial dose of 4 mg doxazosin. Materials and Methods: Between 2000 and 2005, 374 male patients with LUTS and hypertension unresponsive to 4 weeks of 4 mg doxazosin were enrolled. The subjects were randomly classified into 3 groups, 8 mg/day of doxazosin (D group), 4 mg of doxazosin plus 0.2 mg/day of tamsulosin (DT group), and 4 mg doxazosin plus 5 mg/day finasteride (DF group). Patients were evaluated based on their International Prostate Symptom Score (IPSS), quality of life (QOL), uroflowmetry and blood pressure (BP) and adverse events (AEs) at the baseline and 3 and 12 months after treatment. Results: The 269 patients (71.9%) were followed for at least 1 year (D group n=84, DT group n=115, and DF group n=70). The clinical parameters before and after initial 4 mg/day doxazosin were not different among the 3 groups. IPSS improvement after 3 months and maximal flow rate (Qmax) improvement after 3 and 12 months were significantly higher in the D and DT groups than the DF group (p＜0.05).
  • Comparative Effect of Alfuzosin and Tamsulosin on the Contractile

    Comparative Effect of Alfuzosin and Tamsulosin on the Contractile

    LABORATORY SCIENCE Comparative effect of alfuzosin and tamsulosin on the contractile response of isolated rabbit prostatic and iris dilator smooth muscles Possible model for intraoperative floppy-iris syndrome Stefano Palea, PhD, David F. Chang, MD, Moez Rekik, PhD, Alain Regnier, VD, Philippe Lluel, PhD PURPOSE: To compare the pharmacologic properties of tamsulosin and alfuzosin in isolated pros- tatic and iris dilator smooth muscle from pigmented rabbits. SETTING: UROsphere Laboratories, Universite´ Paul Sabatier, Toulouse, France. METHODS: Prostatic and iris dilator smooth muscle strips were placed in organ baths. A con- centration-response curve to phenylephrine was compared before and after incubation with tamsu- losin or alfuzosin. RESULTS: Both drugs were approximately 30 times less potent in iris dilator than prostatic smooth muscle. In the iris, tamsulosin acted as a competitive antagonist starting at the 0.03 mM concentra- tion (pA2 Z 7.96). This is in the same range as the maximum plasma concentration after a 0.4 mg dose of tamsulosin in humans (0.025 mM). The antagonistic effect of alfuzosin in the iris was weaker (calculated mean pA2 value of 5.63 G 0.19). Concentrations with an equipotent antagonistic effect on rabbit iris dilator muscle (3.0 and 10.0 mM) were approximately 100 to 300 times higher than the maximum plasma concentrations after a 10.0 mg dose of alfuzosin in humans (0.032 mM). CONCLUSIONS: Tamsulosin was more effective than alfuzosin at blocking adrenergic contraction of the iris dilator muscle in pigmented rabbits. Both drugs were less potent in the iris than in the prostate, which suggests that an additional iris receptor could be involved.
  • 2021 Formulary List of Covered Prescription Drugs

    2021 Formulary List of Covered Prescription Drugs

    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
  • Otorhinolaryngological Adverse Effects of Urological Drugs ______

    Otorhinolaryngological Adverse Effects of Urological Drugs ______

    REVIEW ARTICLE Vol. 47 (4): 747-752, July - August, 2021 doi: 10.1590/S1677-5538.IBJU.2021.99.06 Otorhinolaryngological adverse effects of urological drugs _______________________________________________ Nathalia de Paula Doyle Maia 1, Karen de Carvalho Lopes 2, Fernando Freitas Ganança 2 1 Programa de Pós-Graduação em Medicina, Otorrinolaringologia da Universidade Federal de São Paulo - Escola Paulista de Medicina - UNIFESP, São Paulo, SP, Brasil; 2 Departamento de Otorrinolaringologia e Cirurgia de Cabeça e Pescoço da Universidade Federal de São Paulo - Escola Paulista de Medicina - UNIFESP, São Paulo, SP, Brasil ABSTRACT ARTICLE INFO Purpose: To describe the otorhinolaryngological adverse effects of the main drugs used Fernando Gananca in urological practice. http://orcid.org/0000-0002-8703-9818 Materials and Methods: A review of the scientific literature was performed using a combination of specific descriptors (side effect, adverse effect, scopolamine, Keywords: sildenafil, tadalafil, vardenafil, oxybutynin, tolterodine, spironolactone, furosemide, Cholinergic Antagonists; hydrochlorothiazide, doxazosin, alfuzosin, terazosin, prazosin, tamsulosin, Adrenergic alpha-1 Receptor desmopressin) contained in publications until April 2020. Manuscripts written in Antagonists; Deamino Arginine Vasopressin English, Portuguese, and Spanish were manually selected from the title and abstract. The main drugs used in Urology were divided into five groups to describe their Int Braz J Urol. 2021; 47: 747-52 possible adverse effects: alpha-blockers, anticholinergics, diuretics, hormones, and phosphodiesterase inhibitors. Results: The main drugs used in Urology may cause several otorhinolaryngological _____________________ adverse effects. Dizziness was most common, but dry mouth, rhinitis, nasal congestion, Submitted for publication: epistaxis, hearing loss, tinnitus, and rhinorrhea were also reported and varies among June 24, 2020 drug classes.